Business
GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million
PARIS, September 26, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/8c67132811506b9f5aae75e4e8696c31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9yW5i62Kvr4O64f5EqRjQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8c67132811506b9f5aae75e4e8696c31","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, September 26, 2025--(BUSINESS WIRE)--Regulatory News:","length":60,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 3,694,665.92 fundraising subscribed by three of its shareholders: Heights Capital, Invus and Alumni Capital (the "Fundraising"). This fundraising follows the EUR 4.5 million private placement completed in early July and uses the same structure of shares and warrants, including pre-funded warrants, as detailed below.","length":645,"tagName":"p"},{"type":"text","content":""As ever, we are grateful to our three existing shareholders for their continued confidence in the strategy we have built and the roadmap we are following." said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "Following the July financing round, their infusion of additional funds amounting to nearly EUR 3.7 million is proof of their ongoing commitment to the development of GS010/LUMEVOQ1. Their support will help us to achieve crucial regulatory milestones, which represent major catalysts for GenSight."","length":547,"tagName":"p"},{"type":"text","content":"The Fundraising is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des marchés financiers – the "AMF"). However, in accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the Eu...